Goldman Sachs
MDNA

Goldman Sachs’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Goldman Sachs’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-36,902
Closed -$151K – 6622
2021
Q1 		$151K Buy
+36,902
New +$150K ﹤0.01% 5740

Other funds holding MDNA

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs's MDNA Position: Q2 2021 in Review

Goldman Sachs sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q2 2021, closing a stake of 36,902 shares — an estimated $151K sold.

Goldman Sachs first reported a position in MDNA in Q1 2021 and held it in 1 quarter. The position peaked at $151K in Q1 2021. 26 funds tracked by Wall St. Rank hold MDNA as of Q2 2021.

  • Goldman Sachs reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q2 2021 after selling out during the quarter.
  • Goldman Sachs sold 36,902 Medicenna Therapeutics Corp. Common Shares shares in Q2 2021, an estimated $151K.
  • Goldman Sachs first reported a position in Medicenna Therapeutics Corp. Common Shares in Q1 2021 and held it in 1 quarter.
  • Goldman Sachs's Medicenna Therapeutics Corp. Common Shares position peaked at $151K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.